WisBusiness: the Podcast with Serafino Fabiano, Eli Lilly and Company - WisBusiness
WisBusiness: the Podcast with Serafino Fabiano, Eli Lilly and Company WisBusiness
Eli Lilly Company News
Eli Lilly launches oral weight-loss drug Foundayo in UK - Reuters
Eli Lilly launches oral weight-loss drug Foundayo in UK Reuters
Lilly’s move to hide Phase 1 pipeline draws mixed reviews - Endpoints News
Lilly’s move to hide Phase 1 pipeline draws mixed reviews Endpoints News
Eli Lilly (LLY) Says Zepbound Cuts Healthcare Costs For Adults Over 55 - simplywall.st
Eli Lilly (LLY) Says Zepbound Cuts Healthcare Costs For Adults Over 55 simplywall.st
Can Eli Lilly's Oncology Portfolio Drive Growth Beyond GLP-1 Drugs? - TradingView
Can Eli Lilly's Oncology Portfolio Drive Growth Beyond GLP-1 Drugs? TradingView
Big, Bold, Breaking Ground: Why Eli Lilly, Amazon And Mastercard Headline Our New Most Innovative Large Companies List - Forbes
Big, Bold, Breaking Ground: Why Eli Lilly, Amazon And Mastercard Headline Our New Most Innovative Large Companies List Forbes
Eli Lilly (NYSE:LLY) Demonstrates High-Growth Leadership and Momentum - ChartMill
Eli Lilly (NYSE:LLY) Demonstrates High-Growth Leadership and Momentum ChartMill
Eli Lilly & Co. stock underperforms Tuesday when compared to competitors - MarketWatch
Eli Lilly & Co. stock underperforms Tuesday when compared to competitors MarketWatch
Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market - PR Newswire
Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market PR Newswire
Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progress - Eli Lilly and Company
Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progress Eli Lilly and Company
Is Eli Lilly and Co (LLY) a Bargain After 3.6% Drop? GF Value Sa - GuruFocus
Is Eli Lilly and Co (LLY) a Bargain After 3.6% Drop? GF Value Sa GuruFocus
Eli Lilly Stock Pulls Back After Hitting Record Highs Last Week - Benzinga
Eli Lilly Stock Pulls Back After Hitting Record Highs Last Week Benzinga
Eli Lilly and Company (LLY)’s Weight-Loss Pill Just Won Its First Race in Europe. Novo Nordisk A/S (NVO) Still Has a Head Start - Yahoo Finance
Eli Lilly and Company (LLY)’s Weight-Loss Pill Just Won Its First Race in Europe. Novo Nordisk A/S (NVO) Still Has a Head Start Yahoo Finance
Lilly files six lawsuits in bid to shut down ‘black market’ for retatrutide - BioPharma Dive
Lilly files six lawsuits in bid to shut down ‘black market’ for retatrutide BioPharma Dive
Eli Lilly takes aim at illicit market for its experimental weight-loss drug - CBS News
Eli Lilly takes aim at illicit market for its experimental weight-loss drug CBS News
Eli Lilly Ripe for Stock Split After Obesity Drug-Fueled Rally - Bloomberg
Eli Lilly Ripe for Stock Split After Obesity Drug-Fueled Rally Bloomberg
Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial - Eli Lilly and Company
Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial Eli Lilly and Company
Is Eli Lilly (LLY) Still the Undisputed Leader in the $150 Billion Obesity Drug Market? - Yahoo Finance
Is Eli Lilly (LLY) Still the Undisputed Leader in the $150 Billion Obesity Drug Market? Yahoo Finance
Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C - Eli Lilly and Company
Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C Eli Lilly and Company
Lilly's Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage of menopause - Eli Lilly and Company
Lilly's Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage of menopause Eli Lilly and Company
Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions - Eli Lilly and Company
Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions Eli Lilly and Company
Lilly announces three acquisitions to build infectious disease portfolio - Eli Lilly and Company
Lilly announces three acquisitions to build infectious disease portfolio Eli Lilly and Company
The divide between Eli Lilly and Novo Nordisk is widening after their latest earnings - CNBC
The divide between Eli Lilly and Novo Nordisk is widening after their latest earnings CNBC
Eli Lilly Posts Higher Revenue on Continued GLP-1 Demand - WSJ
Eli Lilly Posts Higher Revenue on Continued GLP-1 Demand WSJ
Eli Lilly to offer early access to next-gen obesity drug to some patients - Reuters
Eli Lilly to offer early access to next-gen obesity drug to some patients Reuters
Eli Lilly to allow more patients to apply for special access to unapproved obesity drug - STAT
Eli Lilly to allow more patients to apply for special access to unapproved obesity drug STAT
/C O R R E C T I O N -- Eli Lilly and Company/ - PR Newswire
/C O R R E C T I O N -- Eli Lilly and Company/ PR Newswire
Here’s How Much Traders See Eli Lilly Stock Moving After Earnings - Investopedia
Here’s How Much Traders See Eli Lilly Stock Moving After Earnings Investopedia
Lilly reports first-quarter 2026 financial results, raises full year guidance, and highlights momentum of new medicines - Eli Lilly and Company
Lilly reports first-quarter 2026 financial results, raises full year guidance, and highlights momentum of new medicines Eli Lilly and Company
FDA approves Lilly's Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions - Eli Lilly and Company
FDA approves Lilly's Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions Eli Lilly and Company
What is keeping Eli Lilly (NYSE:LLY) in focus as GLP-1 demand surges today? - Kalkine Media
What is keeping Eli Lilly (NYSE:LLY) in focus as GLP-1 demand surges today? Kalkine Media
Lilly commits additional $4.5 billion across Indiana manufacturing sites, opens first dedicated genetic medicine facility - Eli Lilly and Company
Lilly commits additional $4.5 billion across Indiana manufacturing sites, opens first dedicated genetic medicine facility Eli Lilly and Company
Can anyone catch up to Eli Lilly? - PharmaVoice
Can anyone catch up to Eli Lilly? PharmaVoice
CVS Health enhances its direct-to-consumer weight management offerings - CVS Health
CVS Health enhances its direct-to-consumer weight management offerings CVS Health
Breakingviews - COMMENTARY: Eli Lilly is pharma’s latest victim of success - Reuters
Breakingviews - COMMENTARY: Eli Lilly is pharma’s latest victim of success Reuters
Lilly sues six companies over alleged illegal sales of experimental obesity drug retatrutide - Reuters
Lilly sues six companies over alleged illegal sales of experimental obesity drug retatrutide Reuters
Why Is Eli Lilly (LLY) Stock Soaring Today - StockStory
Why Is Eli Lilly (LLY) Stock Soaring Today StockStory
Novo Nordisk says it’s suing Eli Lilly, accusing it of false advertising - NBC News
Novo Nordisk says it’s suing Eli Lilly, accusing it of false advertising NBC News
Eli Lilly gave extraordinary obesity drug access to a 79-year-old patient. Who was it? - STAT
Eli Lilly gave extraordinary obesity drug access to a 79-year-old patient. Who was it? STAT
Eli Lilly (NYSE:LLY): What Could Drive Its Next Growth Chapter? - Kalkine Media
Eli Lilly (NYSE:LLY): What Could Drive Its Next Growth Chapter? Kalkine Media